ClearPoint Neuro (NASDAQ:CLPT) CEO Joseph Burnett Sells 20,000 Shares of Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) CEO Joseph Burnett sold 20,000 shares of ClearPoint Neuro stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $16.12, for a total transaction of $322,400.00. Following the completion of the sale, the chief executive officer owned 11,565 shares of the company’s stock, valued at $186,427.80. This trade represents a 63.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

ClearPoint Neuro Stock Performance

Shares of NASDAQ:CLPT opened at $14.47 on Wednesday. ClearPoint Neuro, Inc. has a 12-month low of $9.76 and a 12-month high of $30.10. The company’s 50 day moving average price is $14.46 and its two-hundred day moving average price is $15.05. The firm has a market cap of $411.24 million, a PE ratio of -17.23 and a beta of 0.91. The company has a quick ratio of 5.56, a current ratio of 6.37 and a debt-to-equity ratio of 1.84.

ClearPoint Neuro (NASDAQ:CLPT) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The business had revenue of $5.36 million during the quarter, compared to analyst estimates of $9.60 million. ClearPoint Neuro had a negative net margin of 67.40% and a negative return on equity of 114.28%. Equities research analysts predict that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

Hedge Funds Weigh In On ClearPoint Neuro

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in ClearPoint Neuro by 1.5% during the third quarter. Vanguard Group Inc. now owns 1,497,637 shares of the company’s stock worth $32,634,000 after acquiring an additional 22,517 shares in the last quarter. Millennium Management LLC grew its holdings in shares of ClearPoint Neuro by 156.3% during the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock valued at $8,813,000 after purchasing an additional 452,043 shares during the last quarter. Geode Capital Management LLC increased its position in ClearPoint Neuro by 107.3% during the 2nd quarter. Geode Capital Management LLC now owns 624,800 shares of the company’s stock worth $7,461,000 after purchasing an additional 323,429 shares in the last quarter. UBS Group AG lifted its stake in ClearPoint Neuro by 132.1% in the 3rd quarter. UBS Group AG now owns 360,705 shares of the company’s stock valued at $7,860,000 after purchasing an additional 205,295 shares during the last quarter. Finally, Lane Generational LLC lifted its stake in ClearPoint Neuro by 20.7% in the 3rd quarter. Lane Generational LLC now owns 311,885 shares of the company’s stock valued at $6,796,000 after purchasing an additional 53,458 shares during the last quarter. Institutional investors and hedge funds own 30.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on CLPT shares. Wall Street Zen lowered ClearPoint Neuro from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, ClearPoint Neuro has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.